ClinicalTrials.gg
CompletedNCT00700518Updated Dec 30, 2008

Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon

A Phase 1 interventional study of placebo cream and Glyceryl Trinitrate in Raynaud's Phenomenon, sponsored by Procris Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2008-12-30.

Sponsored by Procris Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Raynaud Disease with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Raynaud Disease · United States.

Planned enrollment
28th of 33
10 · median 34
Started
2008
with 1 other
Phase 1
3 of 33
none open now
Registered
11th of 33
by date

Among the 33 studies in Raynaud Disease with a site in United States, this one is the 28th largest by planned enrollment, is one of 2 that started in 2008, is one of 3 in phase 1, and was the 11th registered.

Raynaud Disease

81 studies on the registry are indexed under Raynaud Disease; 8 are open to participants now.

Browse Raynaud Disease studies →

Open to participants now

2 of the 33 studies in Raynaud Disease with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Raynaud Disease studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Raynaud Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the blood flow response to topical Glyceryl Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.

03

Conditions studied

  • Raynaud's Phenomenon

Browse trials for

Keywords

  • Raynaud's Syndrome
  • Raynaud's Disease
  • RP
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female volunteers aged between 18 and 50 inclusive
  • Subject has idiopathic RP (patient may have undifferentiated connective tissue disease with positive ANA) diagnosed for more than two (2) years
  • If a female, subject must be non-pregnant and non-lactating
  • The subject has provided written prior to admission to this study

Exclusion criteria

Exclusion Criteria:

  • History of medical illnesses (not considering RP) that in the Investigator's opinion may jeopardize subject's safety or interfere with participation in the study, including but not limited to hemoglobinopathy, hemophilia, clinically significant retinal abnormalities, unstable hypertension, liver diseases, chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases, gout, psychiatric or psychological disorders, CNS trauma or active seizure disorders, allergic or immunologically mediated disorders
  • History in the past five (5) years of drug or alcohol abuse
  • History in the past five (5) years of vascular migraine or other chronic severe headache
  • History in the past five (5) years of autonomic neuropathy or postural hypotension
  • Unwilling or unable to comply with the restrictions outlined in the protocol
  • Current use of smoking cessation treatment, including nicotine patches
  • History of drug allergies, anaphylaxis or laryngeal oedema, including allergy to GTN, propylene/ethylene glycol or common moisturizing creams
  • Use of any nitrate medication or any phosphodiesterase inhibitor within three (3) days prior to or intended use one (1) day following each dosing with study drug
  • Currently treated for hypertension
  • Currently receiving treatment for prevention and/or treatment of RP
  • Use of any medication within 30 days prior to dosing with study medication or scheduled to receive an investigational drug other than during the course of this study
  • Open skin lesions or pathological condition (including, but not limited to, infection) in the area where the study medication is to be applied
  • Use of topical to the hand or fingers within 10 days of treatment with study drug
  • Withdrawal of consent at any time during the study
  • Any condition, which compromises ability to give or to communicate with the investigator as required for the completion of this study
  • Previously enrolled in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Placebo comparator
    1.

    placebo cream applied to 2 adjacent fingers on non-dominant hand one time

    Drug: placebo cream

  • Active comparator
    2

    0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand

    Drug: Glyceryl Trinitrate

  • Active comparator
    3

    1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

    Drug: Glyceryl Trinitrate

  • Active comparator
    4

    1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time

    Drug: Glyceryl Trinitrate

  • Active comparator
    5

    2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

    Drug: Glyceryl Trinitrate

Interventions

  • Drugplacebo cream

    placebo cream applied to 2 adjacent fingers of non-dominant hand one time

  • 0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time

  • 1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

  • 1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

  • 2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

06

What researchers measure

Primary outcomes

  1. Investigate vascular responses to topical Glyceryl Trinitrate versus placebo in patients with Raynaud's using laser Doppler imaging to measure blood flow

    Time frame: 6 visits no less than 10 hours between visits

Secondary outcomes

  1. Evaluate the dose proportionality of the microvascular response to topical Glyceryl Trinitrate

    Time frame: 6 visits no less than 10 hours between visits

  2. Compare the systemic versus topical effect of Glyceryl Trinitrate on vascular response.

    Time frame: 6 visits no less than 10 hours between visits

07

Study locations

1 site
  • University of Iowa-Institute for Clinical and Translational Science
    Iowa City, Iowa 52242, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2008
First posted
Jun 18, 2008
Start
Jun 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
Dec 30, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00700518
Lead sponsor
Procris Pharmaceuticals
First posted
Jun 18, 2008
Start date
Jun 2008
Primary completion
Nov 2008
Completion
Nov 2008
Last update
Dec 30, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion